Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene.

Niyomnaitham S, Parinyanitikul N, Roothumnong E, Jinda W, Samarnthai N, Atikankul T, Suktitipat B, Thongnoppakhun W, Limwongse C, Pithukpakorn M.

PeerJ. 2019 Feb 25;7:e6501. doi: 10.7717/peerj.6501. eCollection 2019.

2.

Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM.

Mol Cancer Ther. 2019 Feb;18(2):399-412. doi: 10.1158/1535-7163.MCT-18-0710. Epub 2018 Dec 5.

PMID:
30518672
3.

Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.

Parinyanitikul N, Tanpipattanakul W, Poovorawan N, Rattananupong T, Laoitthi P, Sithidetphaiboon P, Thanasanvimon S, Sriuranpong V.

Support Care Cancer. 2018 Jul;26(7):2471-2477. doi: 10.1007/s00520-018-4087-3. Epub 2018 Feb 12.

PMID:
29435713
4.

A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes.

Ratanajarusiri T, Sriuranpong V, Sitthideatphaiboon P, Poovoravan N, Vinayanuwat C, Parinyanitikul N, Angspatt P, Thawinwisan W, Tanasanvimon S.

Chemotherapy. 2017;62(2):134-139. doi: 10.1159/000450748. Epub 2016 Dec 20.

PMID:
27997900
5.

Functional consequence of the MET-T1010I polymorphism in breast cancer.

Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM.

Oncotarget. 2015 Feb 20;6(5):2604-14.

6.

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.

Gonzalez-Angulo AM, Parinyanitikul N, Lei X, Mittendorf EA, Zhang H, Valero V, Hunt KK, Hortobagyi GN, Chavez-MacGregor M.

Br J Cancer. 2015 Feb 17;112(4):630-5. doi: 10.1038/bjc.2014.647. Epub 2015 Jan 13.

7.

Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes.

Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM.

Clin Breast Cancer. 2015 Apr;15(2):153-60. doi: 10.1016/j.clbc.2014.09.006. Epub 2014 Oct 2.

PMID:
25454687
8.

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.

Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM.

J Cancer. 2014 Oct 15;5(9):745-53. doi: 10.7150/jca.9696. eCollection 2014.

9.

Mesothelin expression and survival outcomes in triple receptor negative breast cancer.

Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM.

Clin Breast Cancer. 2013 Oct;13(5):378-84. doi: 10.1016/j.clbc.2013.05.001. Epub 2013 Jun 27.

Supplemental Content

Loading ...
Support Center